Detalles de la búsqueda
1.
A simple procedure to identify children with B-lineage acute lymphoblastic leukemia who can be successfully treated with low or moderate intensity: Sequential versus single-point minimal residual disease measurement.
Pediatr Blood Cancer
; 70(6): e30295, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36975157
2.
Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL.
J Immunother Cancer
; 12(6)2024 Jun 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38844406
3.
Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non-high-risk acute lymphoblastic leukemia treated according to the ALL-MB 2008 protocol.
Cancer Med
; 13(8): e7172, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38651186
4.
One-point flow cytometric MRD measurement to identify children with excellent outcome after intermediate-risk BCP-ALL: results of the ALL-MB 2008 study.
J Cancer Res Clin Oncol
; 149(8): 4629-4637, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-36169717
5.
Flow cytometric MRD at the end of consolidation in childhood B-lineage acute lymphoblastic leukemia has significant prognostic value but limited clinical implications: Results of study ALL-MB 2008.
Leuk Res
; 125: 106998, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36566537
6.
A simple algorithm with one flow cytometric MRD measurement identifies more than 40% of children with ALL who can be cured with low-intensity therapy. The ALL-MB 2008 trial results.
Leukemia
; 36(5): 1382-1385, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35322171
7.
A single flow cytometric MRD measurement in children with B-lineage acute lymphocytic leukemia and hyperleukocytosis redefines the requirements of high-risk treatment: Results of the study ALL-MB 2008.
Leuk Res
; 123: 106982, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36332292
Resultados
1 -
7
de 7
1
Próxima >
>>